BridgeMD
Prevention study for Colo-rectal Cancer
Official title Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy
ClinicalTrials.gov ID: NCT06576986
What this study is testing
- What it's testing
- Introduction: In the 2023-2025 period, colorectal cancer (CRC) will be the third most common type of cancer in Brazil. The most commonly used therapeutic approaches are chemotherapy (QTx) and radiotherapy (RTx).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Colorectal tumor in the first oncological treatment
- Age over 18 years old
- Both sexes
- Eligible for protocol with capecitabine alone or associated with oxaliplatin
- Patients WITHOUT colostomy or WITH colostomy in the transverse/descending/sigmoid region
You likely can't join if
- Diagnosis of gastrointestinal carcinoid and stromal tumor (GIST)
- Patients with Ileostomy
- Patients with colostomy in the ascending region of the colon
- Inflammatory bowel diseases: Crohn's and Colitis
- Use of antibiotics and antifungals in the last 15 days
- Use of prebiotic/probiotic and/or synbiotic in the last 15 days
See the full eligibility criteria
- Colorectal tumor in the first oncological treatment
- Age over 18 years old
- Both sexes
- Eligible for protocol with capecitabine alone or associated with oxaliplatin
- Patients WITHOUT colostomy or WITH colostomy in the transverse/descending/sigmoid region
- Patient undergoing Radiotherapy treatment associated with Chemotherapy
- Patients residing in Belo Horizonte and the metropolitan region
- Patients who Accept and sign the Informed Consent Form (TCLE)
- Diagnosis of gastrointestinal carcinoid and stromal tumor (GIST)
- Patients with Ileostomy
- Patients with colostomy in the ascending region of the colon
- Inflammatory bowel diseases: Crohn's and Colitis
- Use of antibiotics and antifungals in the last 15 days
- Use of prebiotic/probiotic and/or synbiotic in the last 15 days
- Use of antidiarrheal medication in the last 15 days
- Presence of fever and mucus discharge
- Pregnant or breastfeeding women
- Patients who refuse to participate in the study.
The study team makes the final eligibility decision.
Where it's taking place
- Belo Horizonte, Minas Gerais, Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Belo Horizonte, Minas Gerais, Brazil. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.